CR-rate ratios with 95% CIs

Slides:

Advertisements

Similar presentations

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

Advertisements

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

1 Flinn I et al. Proc ICML 2013;Abstract 084.

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy? Radioimmunotherapy! Matthew Matasar,

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma by Florian Scherer, David M. Kurtz, Aaron M. Newman, Henning.

CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma Carol D. Jones, Katherine H. Darnell, Roger A.

CCO Independent Conference Highlights

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M

Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma by Raija Ristamäki, Heikki Joensuu, Kimmo Lappalainen, Lasse.

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells by Changchun.

MBL: mostly benign lymphocytes, but…

by Nadine Martel, James Lee, and Philip S. Wells

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell.

Next-generation leukemia immunotherapy

Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization by Margit Schraders, Rolph Pfundt,

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Tax fingerprint in adult T-cell leukemia

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

How I treat elderly patients with myeloma

Nonmyeloablative conditioning for relapsed follicular lymphoma

Superior Survival after Autologous vs

Mechanisms of HIV-associated lymphocyte apoptosis

R-CHOP for Frontline Follicular Lymphoma

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

SOX11 holds mantle cell lymphoma’s key to home

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Mutation Analysis of the Rearranged Immunoglobulin Heavy Chain Genes of Marginal Zone Cell Lymphomas Indicates an Origin From Different Marginal Zone B.

by Fangxin Hong, Thomas M Habermann, Leo I

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.

Lymphoma spread? Target CD47-SIRPα!

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,

by George Z. Rassidakis, Mauricio P. Oyarzo, and L. Jeffrey Medeiros

Anergy: the CLL cell limbo

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Quantifying the risk of non-Hodgkin lymphoma in symptomatic primary care patients aged ≥40 years: a large case–control study using electronic records by.

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,

Box plots showing the relative difference in distribution of mtDNA copy number per cell between patients with ESRD and healthy control subjects frequency.

Figure 2 Peripheral blood lymphocyte subset counts during dimethyl fumarate treatment(A) Lymphocyte subsets were obtained at baseline (n = 21) and at month.

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Effects of DWJM on UCB CD34+-derived cell subsets.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

sIgM levels or signaling and FISH lesions in CLL

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Effect of randomized treatment on all renal events (top) and the composite of all renal events, macrovascular events, or all-cause mortality (bottom) according.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.

Patient Tregs express normal levels of suppression.

by Lapo Alinari, and Kristie A. Blum

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Associations of dialysis session length with mortality and hospitalizations. Associations of dialysis session length with mortality and hospitalizations.

Optimizing therapy for nodal marginal zone lymphoma

Is Skull-Base to Proximal Thigh PET/CT Enough

How I treat T-cell acute lymphoblastic leukemia in adults

Cumulative probability of CIN2 stratified by HPV test results.

Outcomes in patients with PTCL

Presentation transcript:

CR-rate ratios with 95% CIs CR-rate ratios with 95% CIs. CR-rate ratio and P value for a Sup test are calculated using the Cochran–Mantel–Haenszel test stratified by predetermined standard treatment and lymphoma type (mantle cell vs other types). CR-rate ratios with 95% CIs. CR-rate ratio and P value for a Sup test are calculated using the Cochran–Mantel–Haenszel test stratified by predetermined standard treatment and lymphoma type (mantle cell vs other types). P value is calculated based on weighted z statistics for an NI test of CR-rate ratio (BR vs R-CHOP/R-CVP) of 0.88. (Top) BR compared with combined R-CHOP/R-CVP group. (Bottom) Analysis by preassigned treatment group. *CR-rate ratio and P value for a Sup test are calculated using the Cochran–Mantel–Haenszel test stratified by predetermined standard treatment and lymphoma type (mantle cell vs other types). †P value is calculated based on weighted z statistics for an NI test of CR-rate ratio (BR vs R-CHOP/R-CVP) of 0.88. Ian W. Flinn et al. Blood 2014;123:2944-2952 ©2014 by American Society of Hematology